- Home
- HEPS vs LTGO Comparison
HEPS vs LTGO Comparison
Compare HEPS & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HEPS | LTGO |
|---|---|---|
| Founded | 2000 | N/A |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2021 | 2026 |
Fundamental Metrics
Financial Performance| Metric | HEPS | LTGO |
|---|---|---|
| Price | $2.68 | $21.97 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.07 | N/A |
| AVG Volume (30 Days) | 162.6K | ★ 292.6K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $41.29 | N/A |
| Revenue Next Year | $27.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.15 | $17.22 |
| 52 Week High | $3.30 | $25.93 |
Technical Indicators
Market Signals| Indicator | HEPS | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 46.14 | 61.32 |
| Support Level | $2.52 | $18.46 |
| Resistance Level | $2.92 | $25.47 |
| Average True Range (ATR) | 0.12 | 1.87 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 47.75 | 46.72 |
Price Performance
Historical ComparisonAbout HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. It's portfolio offers its retail customers a wide selection of merchandise including electronics and non-electronics (including books, sports, toys, kids and baby products, cosmetics, furniture, etc). The Group derives revenue from the sales of goods, marketplace revenues and other revenues.
About LTGO Latigo Biotherapeutics Inc. Common Stock
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.